CU6 clarity pharmaceuticals ltd

Ann: SABRE topline results, page-36

  1. 8,191 Posts.
    lightbulb Created with Sketch. 2047


    Finally had the chance to read the announcement. Yet another Ann that screams FTD, BTD and best in class along with recent SARTATE - I would be surprised if we didn’t apply or achieve them.


    Huge unmet need in GRPR. This is what our AI friend has to say.



    Question: What percentage of cancers and which cancers don’t express PSA but express GRPR?


    Great question! To clarify, you’re asking about cancers that do not express PSA (Prostate-Specific Antigen) but do express GRPR (Gastrin-Releasing Peptide Receptor), along with what percentage of cancers fall into that category.



    PSA and GRPR Expression Overview



    • PSA is primarily a marker for prostate cancer and is highly specific to prostate epithelial cells.
    • GRPR is expressed in various cancers, including prostate cancer, but also in some non-prostate cancers.






    Cancers That Do NOT Express PSA but Express GRPR



    1. Non-Prostate Cancers with GRPR Expression
      PSA is essentially not expressed outside prostate tissue, so non-prostate cancers generally don’t express PSA but can express GRPR.
    2. Common cancers known to express GRPR but not PSA include:
    • Breast cancer: Many studies show GRPR is overexpressed in breast cancer cells, especially in estrogen receptor-positive subtypes.
    • Lung cancer: Both small cell and non-small cell lung cancers can express GRPR.
    • Gastrointestinal cancers: Pancreatic, colon, and gastric cancers have shown GRPR expression.
    • Bladder cancer: Some bladder cancers express GRPR.
    • Gliomas: Certain brain tumors like gliomas express GRPR but not PSA.






    Percentage of Cancers Expressing GRPR but Not PSA



    PSA expression outside prostate cancer is negligible, so we focus on GRPR:


    • Breast cancer: GRPR expression reported in ~60-80% of cases in various studies.
    • Lung cancer: GRPR expression seen in ~40-70% of cases.
    • Gastrointestinal cancers: Variable, but reports suggest ~30-60% depending on subtype.
    • Bladder cancer: Roughly 40-50% express GRPR.
    • Gliomas: Up to ~50% show GRPR positivity.



    Exact percentages vary depending on detection method (IHC, mRNA), cancer subtype, and study population.





    Summary Table


    Cancer Type

    PSA Expression

    GRPR Expression (%) (approximate)

    1

    Prostate cancer

    High

    High

    2

    Breast cancer

    None

    60-80%

    3

    Lung cancer

    None

    40-70%

    4

    Gastrointestinal

    None

    30-60%

    5

    Bladder cancer

    None

    40-50%

    6

    Gliomas

    None

    ~50%





 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$2.21
Change
0.050(2.31%)
Mkt cap ! $713.4M
Open High Low Value Volume
$2.15 $2.29 $2.13 $2.302M 1.041M

Buyers (Bids)

No. Vol. Price($)
18 10362 $2.21
 

Sellers (Offers)

Price($) Vol. No.
$2.22 11834 22
View Market Depth
Last trade - 12.47pm 16/06/2025 (20 minute delay) ?
CU6 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.